Healthcare Practitioner Training and Education

Medicinal Cannabis Education

Global Health Initiative provides face-to-face and online training for medical practitioners, nurses, pharmacists, and herbalists in medicinal cannabis.


    • Face-to-Face Courses in Medicinal Cannabis: 1-2 day courses, evidence-based courses featuring interactive learning with top medicinal cannabis educator/clinicians from around the globe.


  • Online Courses in Medicinal Cannabis: Global Health Initiative works in collaboration with the Medical Cannabis Institute to provide convenient, comprehensive, evidence-based online training for healthcare professionals. 




Global Health Initiative is pleased to present its first conference and Masterclass in Melbourne in July 2019 focused on medicinal cannabis. The one-day conference is open to all healthcare practitioners who wish to understand more about medicinal cannabis and other nutritional medicine approaches to treatment of common mental health conditions. The one-day Masterclass for doctors, nurses and pharmacists, which follows on from the conference, is focused on prescribing of medicinal cannabis for common mental health conditions and co-morbid chronic pain, and preparing clinicians with knowledge to apply to prescribe medicinal cannabis through the TGA’s SAS-B and Authorised Prescriber Schemes.


Mental Health, Medicinal Cannabis and Nutritional Medicine 

Saturday 20 July 2019

About the Conference


Research indicates that mental health conditions are some of the most common conditions that patients use medicinal cannabis for. Yet few healthcare practitioners know much about medicinal cannabis or other nutritional approaches to the treatment of mental health disorders. This knowledge is vital for healthcare practitioners. Whether or not you want to or can use medicinal cannabis as a treatment option or not, you need to know the facts so that you can answer questions from your patients.

This one-day conference explores what medicinal cannabis is, the endocannabinoid system, delivery methods and pharmacokinetics/ dynamics, its evidence base in the treatment of a range of mental health conditions. It will also cover other nutritional medicine approaches to moods and mental health. The conference features keynote speaker Dr Sue Sisley MD, expert in PTSD and medicinal cannabis, and a host of Australian academics and clinicians.

Who should attend?


This conference is relevant to medical practitioners, psychiatrists, nurses, pharmacists, psychologists, western herbalists, Chinese medicine practitioners and other allied healthcare practitioners who wish to understand more about medicinal cannabis, its evidence base and how it is used to treat common mental health conditions. Registrant numbers are capped at 200.




Sunday 21 July 2019

About the MasterClass


This one-day Masterclass (capped at 60 registrants) follows on from a one-day conference Mental Health, Medicinal Cannabis and Nutritional Medicine, and is focused on learning how to prescribe medicinal cannabis for common mental health conditions and chronic pain. Case studies cover anxiety, PTSD, sleep disorders, depression and co-morbid pain. The Masterclass helps prepare applicants with the knowledge to apply through the TGA’s Special Access Scheme-B and the Authorised Prescriber Scheme. It features experts in medicinal cannabis from the US Dr Ray Gottesfeld MD and Dr Sue Sisley MD, plus a host of Australian clinicians experienced in this field. Attendance at the conference prior to the masterclass is strongly recommended for the required foundation knowledge for this masterclass.

The Masterclass is approved for 40 Category 1 RACGP CPD points. If you are an RACGP member, click here for the RACGP Pre-Activity which must be completed if you wish to claim points. The Post-Activity is included in the Masterclass book provided at the Masterclass.

Who should attend the Masterclass?


 The Masterclass is capped at 60 registrants and is open to doctors, nurses and pharmacists. It is highly recommended that you attend the medicinal cannabis conference on the previous day so that you have thefoundation knowledge for this Masterclass. Note that currently only medical practitioners may access the Authorised Prescriber pathway and whether or not nurse practitioners can access the Special Access Scheme B is dependent on state/territory legislation. 



View Sponsor Bio

Phoenix Life Sciences International Limited is an adaptive healthcare solutions company. The Company’s main initiatives are to advance research on medicinial cannabis and and manufacture cannabis-based products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders. The Company is working with developing nations on integrative programs to improve affordable healthcare and creating industry.  

View Sponsor Bio

VIVO Cannabis’ Beacon Medical brand offers pharmaceutical-grade products grown in small batches at our state-of-the-art facility in Napanee, Ontario. Beacon Medical turns these plants into a variety of Cannabis products for patients to treat their disease. Our focus and pharmaceutical heritage mean that we implicitly understand the needs of prescribing physicians and their patients; and we provide a unique and simplified approach to navigating medical cannabis using the Beacon Cannatypes™ classification system. Beacon Medical is committed to the education of the community and health- care professionals who are interested in learning about Medicinal Cannabis;
and to ensuring that Australian patients have access to safe cannabis medicines.

View Sponsor Bio

Tilray is a global leader in medical cannabis ciltivation, production and research, offering a range of cannabinoid products to patients. pharmaicies and researchers in the European Union, Australia, Canada and the Americas.  

View Sponsor Bio

Entoura is an Australian operated healthcare company, developing and supplying high quality medicinal cannabis products. Established by Professor Ian Brighthope, who over 40 years ago founded Nutrition Care Pharmaceuticals, one of Australia’s exclusive companies in its ability to both formulate and manufacture therapeutic nutraceutical medicines. Entoura is committed to the development of high-quality innovative therapeutics that are supported by outstanding research programs, validated with clinical evidence and disseminated via exceptional education programs. Entoura is active in the Medicinal Cannabis industry, supporting medicinal cannabis research, education, manufacturing and patient access. Our vision is to open new pathways for previously inaccessible practitioner – patient treatment intervention.

View Sponsor Bio

Medlab Clinical is an Australian medical research organisation that formulates innovative solutions to provide the best integrative patient care. We are your partners in providing evidence-based nutraceuticals and pharmaceuticals reinforced by clinical trials and laboratory research. 

Medlab showcases the latest innovative adjunctive medicines designed to improve patients’ quality of life. Among several clinical trials we are currently conducting, notable conditions we aspire to influence via our patented probiotic formulations are Depression and Type-2 Diabetes. We are also pioneering pivotal research utilising Medicinal Cannabis via our NanoCelleä technology in Advanced Cancer Pain and Chemotherapy-Induced Nausea and Vomiting and Seizures. 

View Sponsor Bio

Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (ASX:AGH).

Althea aims to supply pharmaceutical grade medicinal cannabis products to help improve the lives of patients suffering from debilitating conditions.

Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.